M Rosenzwajg, A Gherasim, F Dietsch, M. Beck, N Domis, R Lorenzon, Yannick Chantran, B Bellier, E Vicaut, A Soria, F De Blay, D Klatzmann
{"title":"低剂量白细胞介素-2治疗桦树花粉过敏:第2阶段随机双盲安慰剂对照试验","authors":"M Rosenzwajg, A Gherasim, F Dietsch, M. Beck, N Domis, R Lorenzon, Yannick Chantran, B Bellier, E Vicaut, A Soria, F De Blay, D Klatzmann","doi":"10.1101/2024.09.04.24312986","DOIUrl":null,"url":null,"abstract":"<strong>Background</strong> Regulatory T cells (Tregs) are pivotal in immune tolerance to allergens. Low-dose IL-2 (IL-2<sub>LD</sub>) expands and activates Tregs. We assessed IL-2<sub>LD</sub> efficacy for controlling clinical responses to allergen exposures.","PeriodicalId":501527,"journal":{"name":"medRxiv - Allergy and Immunology","volume":"264 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Low-dose interleukin-2 in birch pollen allergy: a phase-2 randomized double-blind placebo-controlled trial\",\"authors\":\"M Rosenzwajg, A Gherasim, F Dietsch, M. Beck, N Domis, R Lorenzon, Yannick Chantran, B Bellier, E Vicaut, A Soria, F De Blay, D Klatzmann\",\"doi\":\"10.1101/2024.09.04.24312986\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Background</strong> Regulatory T cells (Tregs) are pivotal in immune tolerance to allergens. Low-dose IL-2 (IL-2<sub>LD</sub>) expands and activates Tregs. We assessed IL-2<sub>LD</sub> efficacy for controlling clinical responses to allergen exposures.\",\"PeriodicalId\":501527,\"journal\":{\"name\":\"medRxiv - Allergy and Immunology\",\"volume\":\"264 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Allergy and Immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.09.04.24312986\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Allergy and Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.04.24312986","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景调节性 T 细胞(Tregs)在对过敏原的免疫耐受中起着关键作用。低剂量 IL-2(IL-2LD)可扩增和激活 Tregs。我们评估了 IL-2LD 对控制过敏原暴露临床反应的功效。
Low-dose interleukin-2 in birch pollen allergy: a phase-2 randomized double-blind placebo-controlled trial
Background Regulatory T cells (Tregs) are pivotal in immune tolerance to allergens. Low-dose IL-2 (IL-2LD) expands and activates Tregs. We assessed IL-2LD efficacy for controlling clinical responses to allergen exposures.